Skip to main content

Advertisement

Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4

Fig. 7

miR-192-5p inhibited TRIP13 expression in HCC cells. a-c qRT-PCR and western blot analysis of TRIP13 mRNA in HCC cells transfected with miR-192-5p mimics or miR-192-5p inhibitor. d The putative miR-192-5p binding sequence in the 3′-UTR of TRIP13 (left penal). Luciferase activity of 293 T cells co-transfected with WT or MUT luciferase reporter plasmids and miR-192-5p mimics or negative control (right penal). e-f Cell migration and invasion were measured in HCC cells transfected with miR-192-5p mimics or negative control. g A model depicting the major molecular mechanisms of the miR-192-5p–TRIP13–ACTN4–AKT/mTOR axis in HCC. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page